belnacasan

a NSAID

Also Known As:

(S)-1-((S)-2-1((-(4-amino-3-chloro-phenyl)-methanoyl)-amino)-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide; (S)-3-((1-((S)-1-((S)-2-((1-(4-amino-3-chlorophenyl)methanoyl)amino)-3,3-dimethyl-butanoyl)pyrrolidin-2yl)methanoyl)amino)-4-oxo-butyric acid; 1-((2S)-2-((4-amino-3-chlorobenzoyl)amino)-3,3-dimethylbutanoyl)-N-((2R,3S)-2- ethoxy-5-oxo-tetrahydrofuran-3-yl)-l-prolinamide; L-prolinamide, N-(4-amino-3-chlorobenzoyl)-3-methyl-L-valyl-N-((1S)-2-carboxy-1-formylethyl)-; N-(4-amino-3-chlorobenzoyl)-3-methyl-L-valyl-N-((1S)-2-carboxy-1-formylethyl)-L-prolinamide; O-desethyl-belnacasan; VRT 043198; VRT-043198; VX 765; VX-765; VX-765 hemiketal; VX765

Networked: 67 relevant articles (12 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Gu, Lingui: 2 articles (12/2022 - 01/2022)
2.	Li, Ruihao: 2 articles (12/2022 - 01/2022)
3.	Luo, Xu: 2 articles (12/2022 - 01/2022)
4.	Sun, Mingjiang: 2 articles (12/2022 - 01/2022)
5.	Tao, Yihao: 2 articles (12/2022 - 01/2022)
6.	Xie, Zongyi: 2 articles (12/2022 - 01/2022)
7.	Gao, Li: 2 articles (05/2022 - 10/2021)
8.	Li, Siyao: 2 articles (05/2022 - 10/2021)
9.	Ma, Xiangying: 2 articles (05/2022 - 10/2021)
10.	Qiu, Di: 2 articles (05/2022 - 10/2021)

Related Diseases

1.	Inflammation (Inflammations) 05/01/2023 - "VX-765 is a known pyroptosis inhibitor and has been reported to prevent damage in a variety of diseases by reducing inflammation. " 03/03/2022 - "VX-765 ameliorates inflammation and extracellular matrix accumulation by inhibiting the NOX1/ROS/NF-κB pathway in diabetic nephropathy." 01/01/2022 - "VX-765 ameliorates renal injury and fibrosis in diabetes by regulating caspase-1-mediated pyroptosis and inflammation." 11/01/2020 - "These results suggest that Caspase-1-mediated inflammation occurs early in the disease and raise hope that VX-765, a previously Food and Drug Administration-approved drug for human CNS clinical trials, may be a useful drug to prevent the onset of cognitive deficits and brain inflammation in AD." 05/01/2023 - "VX-765 inhibits pyroptosis and reduces inflammation to prevent acute liver failure by upregulating PPARα expression."
2.	Cognitive Dysfunction 01/01/2019 - "Novel object recognition test indicated that VX765 treatment reversed cognitive dysfunction in septic mice. " 12/01/2022 - "These findings revealed that VX-765 reduced Aβ deposition, pyroptosis, and apoptosis in the ipsilateral hippocampus, which may be associated with reduced secondary degeneration and cognitive decline following focal cortical infarction." 12/01/2022 - "The results revealed that VX-765 treatment ameliorated poststroke cognitive dysfunction after ischemia. " 10/11/2022 - "In mice, Casp1 genetic ablation or VX-765 small molecule inhibition of Casp1 given at onset of cognitive deficits strongly supports the association between microglial inflammation and cognitive impairment. " 10/11/2022 - "Here, VX-765 significantly improved episodic and spatial memory impairment eight months after the onset of cognitive impairment in aged AD mice with significant amyloid beta peptide (Aβ) accumulation and microglial inflammation. "
3.	Infarction (Infarctions) 01/01/2021 - "VX-765 treatment, a pyroptosis inhibitor, significantly reduced the infarct size and improved the function of cardiomyocytes. " 10/01/2018 - "In addition, VX-765 reduced infarction in blood-free, isolated rat hearts indicating at least a portion of injurious caspase-1 activation originates in cardiac tissue. " 01/01/2018 - "VX-765 reduced infarct size (28 vs 48% control; P < 0.05) to a similar extent as IPC (30%; P < 0.05). " 12/01/2022 - "These findings revealed that VX-765 reduced Aβ deposition, pyroptosis, and apoptosis in the ipsilateral hippocampus, which may be associated with reduced secondary degeneration and cognitive decline following focal cortical infarction." 01/01/2020 - "Consequently, pharmacologic inhibition of caspase-1 using vx-765 ameliorated ischemia-induced infarction, neurological deficits, and neuronal injury. "
4.	Epilepsy (Aura) 01/01/2022 - "VX-765 is a safe and effective inhibitor of caspase-1, that was well tolerated in a phase II clinical trial in patients with epilepsy, but its application in DN is still undefined. " 01/01/2016 - "In conclusion, our results suggest that VX-765, a drug that was well tolerated in a 6 wk-long phase II trial in patients with epilepsy, is a promising candidate to achieve disease modification in synucleinopathies by limiting α-syn accumulation." 01/01/2020 - "Vx765, a low molecular weight drug that has proven safe in clinical epilepsy trials, has potential therapeutic value for cerebral ischemia by targeting the canonical inflammasome pathway of pyroptosis." 04/01/2011 - "In this study, the anticonvulsant activity of VX-765 (a selective ICE/caspase-1 inhibitor) was examined in a mouse model of chronic epilepsy with spontaneous recurrent epileptic activity refractory to some common anticonvulsant drugs. " 02/01/2016 - "They include candidates with mechanisms of action similar to those of marketed AEDs (allopregnanolone, brivaracetam, ganaxolone, ICA-105665, NS1209, selurampanel); those with new mechanisms of action (beprodon, VX-765); compounds repurposed for the treatment of epilepsy (biperiden, bumetanide, fenfluramine, melatonin, nalutozan, pitolisant, quinidine, valnoctamide, verapamil); and finally candidates with currently unknown mechanisms of action (JNJ-26489112, UCB0942, YKP3089 (Cenobamate). "
5.	Ischemic Stroke 01/01/2019 - "Current studies have shown the anti-inflammatory properties of vx-765 in various disease; however, the impact of vx-765 on the ischemic stroke is still unclear. " 01/01/2019 - "Vx-765 might be a potential therapeutic drug for ameliorating ischemic stroke." 01/01/2019 - "We found that caspase-1 inhibition by administration of vx-765 ameliorated cerebral injury in mice after ischemic stroke by reducing infarct volume and ameliorating the neurological deficits. " 01/01/2021 - "(3) NLRP3 inflammasome inhibitor MCC950, caspase-1 inhibitor VX-765 and IL-1β inhibitor diacerein attenuated brain edema, minimized hemorrhagic transformation and improved neurological outcome, demonstrating the roles of NLRP3 inflammasome in the hyperglycemia-mediated HT and poor outcome in the ischemic stroke rats with acute hyperglycemia. "

Related Drugs and Biologics

1.	interleukin-1beta-converting enzyme inhibitor
2.	N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamide
3.	Inflammasomes
4.	Amyloid (Amyloid Fibrils)
5.	Amyloid beta-Peptides
6.	Nerve Growth Factor (NGF)
7.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
8.	Ketamine
9.	Fibrin
10.	diacerein

Related Therapies and Procedures

1.	Intraperitoneal Injections